RAAS抑制剂相关高钾血症的门诊处理与1年复发风险
该回顾性队列纳入49571例平均79岁、使用RAASi期间发生高钾血症(钾≥5.3 mEq/L)的老年人,按30天内门诊处理策略分组。1年内34%复发;与无干预相比,停用RAASi者复发累积发生率较低(29%对35%,HR 0.82,95%CI 0.78–0.85),且未增加1年心血管事件或全因死亡风险。
要点
- 停用RAASi与1年高钾复发风险降低相关(HR 0.82,95%CI 0.78–0.85)。
- 停用RAASi未增加1年心血管事件(HR 0.96)或全因死亡(HR 1.05)风险。
- 聚苯乙烯磺酸钠组复发风险更高(HR 1.30,95%CI 1.04–1.63)。
核心结论
- 在RAASi相关高钾血症的老年人中,停用RAASi与最低的复发风险相关,且短期心血管事件或全因死亡风险无明显增加。
研究设计与样本
- 基于人群的回顾性队列研究,纳入49571例平均79岁、使用RAASi期间发生高钾血症(钾≥5.3 mEq/L)的老年人。
- 按30天内门诊药物调整分为无干预、停用RAASi、减少RAASi剂量、新增利尿剂、增加利尿剂剂量或使用聚苯乙烯磺酸钠。
- 主要结局为高钾血症复发,次要结局为1年内心血管事件和全因死亡。
主要发现
- 接受药物干预者占23%,其中停用RAASi最常见(74%),其次为减少RAASi剂量(15%)、增加利尿剂(7%)、新增利尿剂(3%)和聚苯乙烯磺酸钠(1%)。
- 1年内共发生16977例(34%)高钾血症复发事件。
- 与无干预(35%)相比,停用RAASi者复发累积发生率较低(29%;HR 0.82,95%CI 0.78–0.85)。
- 减少RAASi剂量(36%;HR 0.94,95%CI 0.86–1.02)、新增利尿剂(32%;HR 0.95,95%CI 0.78–1.17)或增加利尿剂(38%;HR 0.99,95%CI 0.87–1.12)与无干预无差异。
- 聚苯乙烯磺酸钠组复发发生率更高(55%;HR 1.30,95%CI 1.04–1.63)。
关键数值与推荐
- 高钾血症定义为钾≥5.3 mEq/L。
- 停用RAASi与1年心血管事件风险无增加相关(HR 0.96,95%CI 0.91–1.02)。
- 停用RAASi与1年全因死亡风险无增加相关(HR 1.05,95%CI 0.96–1.15)。
临床怎么用
- 对RAASi相关高钾血症的老年患者,停用RAASi可作为降低复发风险的策略之一,且短期未观察到心血管事件或死亡风险增加。
- 减少RAASi剂量或调整利尿剂在本研究中未显著降低复发风险,聚苯乙烯磺酸钠与复发风险升高相关。
局限性
- 本研究为回顾性队列研究,处理策略非随机分配,可能存在残余混杂。
- 研究对象为老年人(平均79岁),结论外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The optimal ambulatory management of renin-angiotensin-aldosterone system inhibitor (RAASi)-related hyperkalemia to reduce the risk of recurrence is unknown. We examined the risk of hyperkalemia recurrence on the basis of outpatient pharmacologic changes following an episode of RAASi-related hyperkalemia. DESIGN: We performed a population-based, retrospective cohort study of older adults (n=49,571; mean age 79 years) who developed hyperkalemia (potassium ≥5.3 mEq/L) while on a RAASi and were grouped as follows: no intervention, RAASi discontinuation, RAASi dose decrease, new diuretic, diuretic dose increase, or sodium polystyrene sulfonate within 30 days. The primary outcome was hyperkalemia recurrence, with secondary outcomes of cardiovascular events and all-cause mortality within 1 year. RESULTS: Among patients who received a pharmacologic intervention (23% of the cohort), RAASi discontinuation was the most commonly prescribed strategy (74%), followed by RAASi decrease (15%), diuretic increase (7%), new diuretic (3%), and sodium polystyrene sulfonate (1%). A total of 16,977 (34%) recurrent hyperkalemia events occurred within 1 year. Compared with no intervention (35%, referent), the cumulative incidence of recurrent hyperkalemia was lower with RAASi discontinuation (29%; hazard ratio, 0.82; 95% confidence interval, 0.78 to 0.85), whereas there was no difference with RAASi dose decrease (36%; hazard ratio, 0.94; 95% confidence interval, 0.86 to 1.02), new diuretic (32%; hazard ratio, 0.95; 95% confidence interval, 0.78 to 1.17), or diuretic increase (38%; hazard ratio, 0.99; 95% confidence interval, 0.87 to 1.12) and a higher incidence with sodium polystyrene sulfonate (55%; hazard ratio, 1.30; 95% confidence interval, 1.04 to 1.63). RAASi discontinuation was not associated with a higher risk of 1-year cardiovascular events (hazard ratio, 0.96; 95% confidence interval, 0.91 to 1.02) or all-cause mortality (hazard ratio, 1.05; 95% confidence interval, 0.96 to 1.15) compared with no intervention. CONCLUSIONS: Among older adults with RAASi-related hyperkalemia, RAASi discontinuation is associated with the lowest risk of recurrent hyperkalemia, with no apparent increase in short-term risks for cardiovascular events or all-cause mortality.
引用
- Hundemer GL, Talarico R, Tangri N, et al. Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence. Clin J Am Soc Nephrol. 2021. PMID: 33608262. doi:10.2215/CJN.12990820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。